Cargando…
The Value of Sentinel Lymph Node Mapping for the Staging of Node-Negative Colon Cancer: Propensity Score and Mediation Analyses
OBJECTIVES: Mediation analysis to assess the protective impact of sentinel lymph node (SLN) mapping on prognosis and survival of patients with colon cancer through a more precise evaluation of the lymph node (LN) status. BACKGROUND: Up to 20% of patients with node-negative colon cancer develop disea...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455289/ https://www.ncbi.nlm.nih.gov/pubmed/37635823 http://dx.doi.org/10.1097/AS9.0000000000000084 |
_version_ | 1785096416645873664 |
---|---|
author | Weixler, Benjamin Ramser, Michaela Warschkow, Rene Viehl, Carsten T. Vaughan-Shaw, Peter G. Zettl, Andreas Kettelhack, Christoph Zuber, Markus |
author_facet | Weixler, Benjamin Ramser, Michaela Warschkow, Rene Viehl, Carsten T. Vaughan-Shaw, Peter G. Zettl, Andreas Kettelhack, Christoph Zuber, Markus |
author_sort | Weixler, Benjamin |
collection | PubMed |
description | OBJECTIVES: Mediation analysis to assess the protective impact of sentinel lymph node (SLN) mapping on prognosis and survival of patients with colon cancer through a more precise evaluation of the lymph node (LN) status. BACKGROUND: Up to 20% of patients with node-negative colon cancer develop disease recurrence. Conventional histopathological LN examination may be limited in describing the real metastatic burden of LN. METHODS: Data of 312 patients with stage I & II colon cancer was collected prospectively. Patients were either staged using intraoperative SLN mapping with multilevel sectioning and immunohistochemical staining of the SLN or conventional techniques. The value of the SLN mapping for the detection of truly node-negative patients was assessed using Cox regression and mediation analysis. RESULTS: SLN mapping was performed in 143 patients. Disease recurrence was observed in 13 (9.1%) patients staged with SLN mapping and in 27 (16%) staged conventionally. Five-year overall survival (OS) rate was 82.7% (95% confidence interval [CI], 76.5–89.4%) with SLN mapping compared with 65.8% (95% CI, 58.8–73.7%). Five-year cancer-specific survival (CSS) was 95.1% (95% CI, 91.3–99.0%) with SLN mapping compared with 92.5% (95% CI, 88.0–97.2%). Node-negative staging with SLN mapping was associated with significantly better OS (hazard ratio [HR], 0.64; 95% CI, 0.56–0.72; P < 0.001) and CSS (HR, 0.49; 95% CI, 0.39–0.61; P < 0.001) in multivariate analysis. Mediation analysis confirmed a direct protective effect of SLN mapping on OS (HR, 0.78; 95% CI, 0.52–0.96; P < 0.01) and disease-free survival (DFS) (HR, 0.75; 95% CI, 0.48–0.89; P < 0.01). CONCLUSIONS: Staging performed by SLN mapping with multilevel sectioning provides more accurate results than conventional staging. The observed clinically relevant and statistically significant benefit in OS and DFS is explained by a more accurate detection of positive LN by SLN mapping. |
format | Online Article Text |
id | pubmed-10455289 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Wolters Kluwer Health, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-104552892023-08-26 The Value of Sentinel Lymph Node Mapping for the Staging of Node-Negative Colon Cancer: Propensity Score and Mediation Analyses Weixler, Benjamin Ramser, Michaela Warschkow, Rene Viehl, Carsten T. Vaughan-Shaw, Peter G. Zettl, Andreas Kettelhack, Christoph Zuber, Markus Ann Surg Open Original Study OBJECTIVES: Mediation analysis to assess the protective impact of sentinel lymph node (SLN) mapping on prognosis and survival of patients with colon cancer through a more precise evaluation of the lymph node (LN) status. BACKGROUND: Up to 20% of patients with node-negative colon cancer develop disease recurrence. Conventional histopathological LN examination may be limited in describing the real metastatic burden of LN. METHODS: Data of 312 patients with stage I & II colon cancer was collected prospectively. Patients were either staged using intraoperative SLN mapping with multilevel sectioning and immunohistochemical staining of the SLN or conventional techniques. The value of the SLN mapping for the detection of truly node-negative patients was assessed using Cox regression and mediation analysis. RESULTS: SLN mapping was performed in 143 patients. Disease recurrence was observed in 13 (9.1%) patients staged with SLN mapping and in 27 (16%) staged conventionally. Five-year overall survival (OS) rate was 82.7% (95% confidence interval [CI], 76.5–89.4%) with SLN mapping compared with 65.8% (95% CI, 58.8–73.7%). Five-year cancer-specific survival (CSS) was 95.1% (95% CI, 91.3–99.0%) with SLN mapping compared with 92.5% (95% CI, 88.0–97.2%). Node-negative staging with SLN mapping was associated with significantly better OS (hazard ratio [HR], 0.64; 95% CI, 0.56–0.72; P < 0.001) and CSS (HR, 0.49; 95% CI, 0.39–0.61; P < 0.001) in multivariate analysis. Mediation analysis confirmed a direct protective effect of SLN mapping on OS (HR, 0.78; 95% CI, 0.52–0.96; P < 0.01) and disease-free survival (DFS) (HR, 0.75; 95% CI, 0.48–0.89; P < 0.01). CONCLUSIONS: Staging performed by SLN mapping with multilevel sectioning provides more accurate results than conventional staging. The observed clinically relevant and statistically significant benefit in OS and DFS is explained by a more accurate detection of positive LN by SLN mapping. Wolters Kluwer Health, Inc. 2021-07-26 /pmc/articles/PMC10455289/ /pubmed/37635823 http://dx.doi.org/10.1097/AS9.0000000000000084 Text en Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Original Study Weixler, Benjamin Ramser, Michaela Warschkow, Rene Viehl, Carsten T. Vaughan-Shaw, Peter G. Zettl, Andreas Kettelhack, Christoph Zuber, Markus The Value of Sentinel Lymph Node Mapping for the Staging of Node-Negative Colon Cancer: Propensity Score and Mediation Analyses |
title | The Value of Sentinel Lymph Node Mapping for the Staging of Node-Negative Colon Cancer: Propensity Score and Mediation Analyses |
title_full | The Value of Sentinel Lymph Node Mapping for the Staging of Node-Negative Colon Cancer: Propensity Score and Mediation Analyses |
title_fullStr | The Value of Sentinel Lymph Node Mapping for the Staging of Node-Negative Colon Cancer: Propensity Score and Mediation Analyses |
title_full_unstemmed | The Value of Sentinel Lymph Node Mapping for the Staging of Node-Negative Colon Cancer: Propensity Score and Mediation Analyses |
title_short | The Value of Sentinel Lymph Node Mapping for the Staging of Node-Negative Colon Cancer: Propensity Score and Mediation Analyses |
title_sort | value of sentinel lymph node mapping for the staging of node-negative colon cancer: propensity score and mediation analyses |
topic | Original Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455289/ https://www.ncbi.nlm.nih.gov/pubmed/37635823 http://dx.doi.org/10.1097/AS9.0000000000000084 |
work_keys_str_mv | AT weixlerbenjamin thevalueofsentinellymphnodemappingforthestagingofnodenegativecoloncancerpropensityscoreandmediationanalyses AT ramsermichaela thevalueofsentinellymphnodemappingforthestagingofnodenegativecoloncancerpropensityscoreandmediationanalyses AT warschkowrene thevalueofsentinellymphnodemappingforthestagingofnodenegativecoloncancerpropensityscoreandmediationanalyses AT viehlcarstent thevalueofsentinellymphnodemappingforthestagingofnodenegativecoloncancerpropensityscoreandmediationanalyses AT vaughanshawpeterg thevalueofsentinellymphnodemappingforthestagingofnodenegativecoloncancerpropensityscoreandmediationanalyses AT zettlandreas thevalueofsentinellymphnodemappingforthestagingofnodenegativecoloncancerpropensityscoreandmediationanalyses AT kettelhackchristoph thevalueofsentinellymphnodemappingforthestagingofnodenegativecoloncancerpropensityscoreandmediationanalyses AT zubermarkus thevalueofsentinellymphnodemappingforthestagingofnodenegativecoloncancerpropensityscoreandmediationanalyses AT weixlerbenjamin valueofsentinellymphnodemappingforthestagingofnodenegativecoloncancerpropensityscoreandmediationanalyses AT ramsermichaela valueofsentinellymphnodemappingforthestagingofnodenegativecoloncancerpropensityscoreandmediationanalyses AT warschkowrene valueofsentinellymphnodemappingforthestagingofnodenegativecoloncancerpropensityscoreandmediationanalyses AT viehlcarstent valueofsentinellymphnodemappingforthestagingofnodenegativecoloncancerpropensityscoreandmediationanalyses AT vaughanshawpeterg valueofsentinellymphnodemappingforthestagingofnodenegativecoloncancerpropensityscoreandmediationanalyses AT zettlandreas valueofsentinellymphnodemappingforthestagingofnodenegativecoloncancerpropensityscoreandmediationanalyses AT kettelhackchristoph valueofsentinellymphnodemappingforthestagingofnodenegativecoloncancerpropensityscoreandmediationanalyses AT zubermarkus valueofsentinellymphnodemappingforthestagingofnodenegativecoloncancerpropensityscoreandmediationanalyses |